Volume 17, Issue 8, Pages (December 2014)

Slides:

Advertisements

Similar presentations

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,

Advertisements

Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.

Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,

Volume 14, Issue 8, Pages (December 2011)

Volume 16, Issue 6, Pages (September 2013)

Ulcerative Colitis Treatment Patterns and Cost of Care

Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual.

Volume 15, Issue 8, Pages (December 2012)

In search of optimal compression therapy for venous leg ulcers: A meta-analysis of studies comparing divers bandages with specifically designed stockings

Volume 18, Issue 4, Pages (June 2015)

Volume 18, Issue 5, Pages (July 2015)

Mapping the COPD Assessment Test onto EQ-5D

Volume 15, Issue 2, Pages (March 2012)

Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results Becky Pennington, MSc,

Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-

Volume 17, Issue 2, Pages (March 2014)

Volume 14, Issue 1, Pages (January 2011)

Volume 18, Issue 4, Pages (June 2015)

Volume 15, Issue 1, Pages S20-S28 (January 2012)

Volume 17, Issue 8, Pages (December 2014)

Volume 14, Issue 8, Pages (December 2011)

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Volume 15, Issue 2, Pages (March 2012)

Volume 15, Issue 6, Pages (September 2012)

Volume 14, Issue 8, Pages (December 2011)

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Volume 15, Issue 1, Pages (January 2012)

Volume 15, Issue 2, Pages (March 2012)

State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings

Examining the Value of Menopausal Symptom Relief Among US Women

Volume 17, Issue 2, Pages (March 2014)

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico Kely Rely, Rosa María.

Value in Health Regional Issues

Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

The Effect of a Connexin43-Based Peptide on the Healing of Chronic Venous Leg Ulcers: A Multicenter, Randomized Trial Gautam S. Ghatnekar, Christina.

Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico Kely Rely, Rosa María.

The Process of Privatization of Health Care Provision in Poland

In search of optimal compression therapy for venous leg ulcers: A meta-analysis of studies comparing divers bandages with specifically designed stockings

State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings

Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea Bo-Ra-Mi Kim, MPH, Tae-Jin Lee, PhD,

Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: A randomized clinical trial Eliot N. Mostow,

Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Value in Health Regional Issues

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,

What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.

Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia in Guatemala Benjamin Cruz Rodriguez, MD, Sergio Leal, MD, Gonzalo Calvimontes,

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Omneya Mohamed, PhD, David H. Kreling, PhD

Analysis of Excess Direct Medical Costs of Vision Impairment in Taiwan

Value in Health Regional Issues

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective Bruno Salgado Riveros,

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers Valentina.

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Value in Health Regional Issues

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L.

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Social Cost of Substance Abuse in Russia

Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD

A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina Joaquín.

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Volume 17, Issue 8, Pages 801-813 (December 2014) Cost-Effectiveness of Three Adjunct Cellular/Tissue-Derived Products Used in the Management of Chronic Venous Leg Ulcers Marissa J. Carter, PhD, MA, Curtis Waycaster, PhD, Kathleen Schaum, MS, Adrienne M. Gilligan, PhD Value in Health Volume 17, Issue 8, Pages 801-813 (December 2014) DOI: 10.1016/j.jval.2014.08.001 Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Trial flow diagram showing retrieval and selection of articles for model input. Value in Health 2014 17, 801-813DOI: (10.1016/j.jval.2014.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Health states of VLUs for Markov modeling. Each treatment pathway involved three Markov health states: unhealed, healed, and dead. The unhealed state was equated to having a VLU, and the healed state was equated to having a healed VLU. The bidirectional arrow between the unhealed and healed states in the Markov diagram represents ulcer recurrence. VLU, venous leg ulcer. Value in Health 2014 17, 801-813DOI: (10.1016/j.jval.2014.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Comparison of healed wound weeks among SC and three cellular/tissue-derived product treatment approaches in relation to SC for the management of venous leg ulcers. ECM, extracellular matrix; HSE, human skin equivalent; LSE, living skin equivalent; SC, standard care. Value in Health 2014 17, 801-813DOI: (10.1016/j.jval.2014.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Comparison of expected wound closure rates among three cellular/tissue-derived product treatment approaches in relation to SC for the management of venous leg ulcers. ECM, extracellular matrix; HSE, human skin equivalent; LSE, living skin equivalent; SC, standard care. Value in Health 2014 17, 801-813DOI: (10.1016/j.jval.2014.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 5 Comparison of cumulative costs among three cellular/tissue-derived product treatment approaches in relation to SC for the management of venous leg ulcers. ECM, extracellular matrix; HSE, human skin equivalent; LSE, living skin equivalent; SC, standard care. Value in Health 2014 17, 801-813DOI: (10.1016/j.jval.2014.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 6 Tornado diagram demonstrating the influence of parameter uncertainty on the expected cost of therapy. ECM, extracellular matrix; SC, standard care. Value in Health 2014 17, 801-813DOI: (10.1016/j.jval.2014.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 7 Probabilistic sensitivity analysis by treatment. Each point on the plot corresponds to one trial in the Monte-Carlo simulation comparing the incremental effectiveness and incremental costs of therapy. Costs for SC and ECM were consistently the lowest and effectiveness the highest for the treatment of venous leg ulcers. ECM, extracellular matrix; HSE, human skin equivalent; LSE, living skin equivalent; SC, standard care. Value in Health 2014 17, 801-813DOI: (10.1016/j.jval.2014.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions